Lion's Mane Studies: What the Human Trials Actually Show

By Peter Orpen, Co-Owner, Teelixir

Most lion’s mane content reviews benefits. This article reviews the studies themselves — their design quality, sample sizes, replication state, and which findings have held up across independent trials.

There is a real evidence base here. There are also real gaps. The human trial picture looks different from what supplement marketing typically presents — and understanding the difference matters if you are making a decision based on evidence rather than enthusiasm. This is a review of 11 validated human and clinical studies on Hericium erinaceus, cited individually below with links to the primary source, structured around what the data has actually confirmed, what it has shown only partially, and what remains unconfirmed in humans.

Why Lion's Mane Is Biologically Unusual

Two compound families make Hericium erinaceus unique among edible fungi. Hericenones are found in the fruiting body; erinacines are found primarily in the mycelium. Both are the subject of ongoing research into their potential effects on nerve growth factor (NGF) pathways — which are thought to play a role in neuronal maintenance.

NGF declines with age. Compounds that stimulate it naturally are rare. A 2025 systematic review (PMID: 40626304) confirmed that erinacines are among the most potent natural NGF stimulators identified to date, with some variants capable of crossing the blood-brain barrier — a significant finding for neuroprotection research.

The NGF Research Focus is what separates lion's mane from generic mushroom supplements. While it contains various compounds, its most studied area in research is neurological — with ongoing investigation into potential effects on neurotrophic factors. This focus explains why it has been traditionally used in cognitive and mood support rather than metabolic or cardiovascular applications.

"Erinacines are among the most potent natural NGF stimulators identified to date, with some variants capable of crossing the blood-brain barrier." — PMID: 40626304, Systematic Review 2025

Cognitive Function: The Strongest Human Evidence

The cognitive evidence is the most-established area for lion's mane in humans. Here is what the controlled trials show.

Mori 2009 (PMID: 18844328) — the landmark trial. Thirty adults aged 50–80 with mild cognitive impairment were randomised to 3g per day of lion's mane powder or placebo for 16 weeks. The treatment group showed significant improvements in cognitive function scores. Critically, when supplementation stopped, the benefits reversed within 4 weeks. This tells you two things: the effect is real, and it is ongoing rather than curative. At doses used in studies, continuous supplementation appears necessary to maintain the effect.

Docherty 2023 (PMID: 38004235). Forty-one healthy young adults received 1.8g per day of lion's mane extract for 28 days in a double-blind, parallel-groups pilot study. Participants performed the Stroop task significantly faster (p=0.005) 60 minutes after a single dose, and showed a non-significant trend toward reduced subjective stress after 28 days (p=0.051) — the authors describe this as tentative given the small sample size. Sleep was not a measured outcome in this study. The acute-effect finding was novel — previous studies had focused on chronic supplementation only.

2025 acute cross-over study (PMID: 40276537). A double-blind, randomised, placebo-controlled cross-over study gave 18 healthy adults (aged 18–35) a single 3g acute dose of standardised lion's mane fruiting-body extract. There was no significant effect on composite measures of cognitive function or mood at 90 minutes post-dose. One isolated positive finding emerged on a pegboard (psychomotor) test. The authors concluded any acute benefit may be task-specific rather than a broad cognitive effect.

2025 PROSPERO-registered systematic review (PMID: 40959699). A registered systematic review synthesising 5 RCTs, 15 laboratory studies, 3 pilot clinical trials, 1 cohort study and 1 case report confirmed the overall cognitive and mood benefits from controlled human trials. No serious adverse events were reported across the included studies. This meta-analysis is the most comprehensive synthesis of the human evidence base to date.

Clinical Trial Doses — Cognitive Function

Mood, Anxiety, and Sleep

Lion's mane is not a direct anxiolytic. It does not work on GABA receptors the way pharmaceuticals do. However, it contains compounds that are the subject of ongoing research into potential effects on mood and wellbeing through various pathways.

Nagano 2010 (PMID: 20834180). Thirty menopausal women were randomised to cookies containing lion's mane extract or placebo for 4 weeks. The treatment group showed significantly lower depression and anxiety scores compared to placebo. A small study, but rigorous in design.

Vigna 2019 (PMID: 31118969). Overweight and obese patients were assessed for mood and sleep after lion's mane supplementation. Improved mood and sleep disorder scores were found, and pro-BDNF and BDNF were identified as potential biomarkers — linking NGF stimulation to mood outcomes.

Grozier 2022 (PMID: 36582308) — the important null finding. Twenty-four college-age adults received 10g per day of lion's mane for 4 weeks in a single-blind, placebo-controlled trial. This study found no significant effect on ANY measured variable — metabolic flexibility, substrate oxidation, or cognitive performance (Stroop and mental arithmetic tasks). It did not assess subjective stress or sleep. This null finding matters: not every lion's mane trial finds an effect, and research claiming broad benefits should be read carefully.

What’s Been Replicated vs What Hasn’t

Replication is the real test of evidence. A single finding in a single trial is a lead, not a conclusion. Here is an honest assessment of which lion’s mane findings have independent confirmation — and which remain single-trial results.

Cognitive function — partial replication. Mori 2009 (PMID: 18844328) found significant cognitive improvement in older adults with mild cognitive impairment. Docherty 2023 (PMID: 38004235) independently found both acute and chronic cognitive benefits in healthy young adults. Different populations, different protocols, same directional finding. That is partial replication — the effect appears real across demographics, but the trials are not yet large enough or sufficiently uniform to draw definitive conclusions about effect size. A separate 2025 acute cross-over study (PMID: 40276537) did NOT replicate an acute composite cognitive effect at 90 minutes — it found only an isolated positive result on a psychomotor (pegboard) test, a genuinely mixed data point rather than confirmatory replication. The 2025 PROSPERO-registered systematic review (PMID: 40959699) synthesised 5 RCTs and confirmed the overall cognitive and mood direction.

Mood and anxiety — small trials, consistent direction. Nagano 2010 (PMID: 20834180) showed mood and anxiety reductions in menopausal women. Vigna 2019 (PMID: 31118969) found improved mood scores in overweight patients. Docherty 2023 found reduced stress scores in healthy young adults. Three trials, three different populations, same direction. But all three were small (n=30–41), and no large-scale RCT has used anxiety as its primary outcome. The mood findings show consistency across studies — though further research is needed to confirm these effects at scale.

Sleep — secondary outcome only. Sleep improvement appears as a secondary outcome in Vigna 2019 (PMID: 31118969), which measured mood and sleep-disorder symptoms in overweight/obese patients. No trial has used sleep as its primary outcome, and Grozier 2022 (PMID: 36582308) did not assess sleep at all. Most studies on sleep mechanisms were animal or in vitro models. Human evidence is limited to secondary-outcome data from a small number of trials.

Preclinical mechanisms — have yet to be confirmed in humans. Most mechanistic research — including studies on NGF synthesis pathways, amyloid-beta effects, tau phosphorylation modulation, and peripheral nerve regeneration — has been conducted in animal or in vitro models. These areas remain the subject of ongoing research in human trials. Supplement content that presents preclinical findings as established human outcomes is overstating the current data.

The pattern: Lion’s mane has the most robust cognitive and mood evidence base among functional mushrooms. The findings that have been tested repeatedly point in the same direction. The caveat is that most human trials are small, short-duration, and conducted without long-term follow-up. The evidence base is growing, not settled.

What the Evidence Does Not Show

Honest limitations matter more than the positive findings for building real trust. Here is what the current research does NOT demonstrate:

• The four-week supplementation study (PMID: 36582308) found no significant effect on metabolic flexibility, substrate oxidation, or cognitive performance at 10g per day — this trial found no benefit on any measured outcome.
• Most studies on the underlying mechanisms — amyloid clearance, tau phosphorylation, BDNF expression — were conducted in animal or in vitro models. Human evidence is limited to small pilot studies.
• There is no head-to-head clinical trial comparing lion's mane to any pharmaceutical cognitive enhancer or antidepressant.
• The ALS clinical review (PMID: 38141002) did not demonstrate efficacy for motor neuron disease in humans. Mechanistic rationale exists; clinical data does not.
• Long-term safety data beyond 49 weeks does not exist in published human trials.
• No Cochrane Review has yet synthesised the lion's mane evidence base — a notable gap in independent quality assessment.

From Our Formulations: What We Observe at Teelixir

Our lion's mane extract is sourced from Xi'an Lifewe (Yes Herbs), China, using a dual-extract process — both ethanol and water extraction. This matters because hericenones are fat-soluble (require ethanol extraction) while beta-glucans are water-soluble. A single-solvent extract will miss one fraction or the other.

Our current batch (COA: C24051507, May 2024) tests at 31.7% beta-glucan against a minimum specification of 30%. The extraction ratio is 10:1 (10kg fruiting body yields 1kg extract). We use fruiting body only — which means our product is high in hericenones but does not contain significant erinacine content. Erinacines are concentrated in the mycelium. If erinacines are specifically what you are seeking — relevant for neurodegeneration research contexts, where the key pilot trial used erinacine A-enriched mycelium — a mycelium-based product is more appropriate. See our dedicated dementia evidence review for the full trial analysis. Our pure 1:1 fruiting body powder offers the full-spectrum whole-food alternative.

Heavy metal testing on batch C24051507: lead pass (limit 3.0mg/kg), arsenic pass (limit 2.0mg/kg), cadmium pass (limit 1.0mg/kg), mercury pass (limit 0.1mg/kg). Microbiology: E. coli negative, Salmonella negative. GMO free. Shelf life 24 months.

What This Means in Practice

Based on the reviewed evidence, here is practical guidance for considering lion's mane supplementation.

You can start with 1–2g daily for at least 4 weeks before assessing your response. You may increase to 3g per day based on the Mori 2009 dose. Aim for consistency rather than cycling. Consider pairing with ashwagandha if you are also managing stress — they address different but complementary pathways (NGF stimulation versus cortisol modulation). Together with consistent sleep habits, lion's mane appears to have an additive effect on sleep quality based on the available data.

When lion's mane is unlikely to help or may not be appropriate: Avoid if you have a known mushroom or fungal allergy. Not suitable as a standalone intervention for diagnosed anxiety or depressive disorders. May not work for those seeking a nootropic with stimulant-like effects — the mechanism is neurotropic and gradual. If you are taking antipsychotic medications, consult your prescribing doctor — a 2025 review examined theoretical interactions in this context (PMID: 39935672). Not recommended without medical supervision if you have an autoimmune condition, due to immune-modulatory activity in preclinical studies.

Safety Profile

The 2025 PROSPERO-registered systematic review (PMID: 40959699) found no serious adverse events across the 5 RCTs synthesised. Most studies using 1.8–3g per day for up to 16 weeks showed lion's mane to be well-tolerated. Minor gastrointestinal discomfort was noted in a small number of participants across individual trials.

Most safety and mechanistic studies to date have been conducted in animal or in vitro models. Further research is needed to establish long-term human safety profiles. Consult your healthcare professional if you are managing any chronic health condition or taking prescription medication before starting supplementation.

Related Articles in This Series

• Lion's Mane Dosage Guide: Clinical Trial Doses, Extract Conversions and Timing
• Lion's Mane Side Effects: Safety Profile Review
• Lion's Mane for Seniors: The Strongest Human Evidence
• Lion's Mane for Brain Fog: What the Evidence Actually Shows
• Lion's Mane for Anxiety: What the Research Actually Shows

Frequently Asked Questions

Disclaimer: This article is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease or health condition. The information presented reflects the current state of published research and should not replace professional medical advice. Always consult your healthcare professional before starting any new supplement, particularly if you are pregnant, breastfeeding, managing a chronic health condition, or taking prescription medications.

Continue Your Research

• Broader benefits review: Lion’s Mane Benefits: What 571 Studies Actually Show
• How lion’s mane is thought to work: The NGF Mechanism and Dual-Extract Advantage
• Lion’s mane for dementia and Alzheimer’s: What the Human Trials Actually Show
• Lion’s Mane for Seniors: The Strongest Human Evidence
• Lion’s Mane Dosage Guide: Clinical Trial Doses, Extract Conversions and Timing
• Lion’s Mane Side Effects: Safety Profile Review
• Lion’s Mane for Anxiety: What the Research Actually Shows
• Lion’s Mane vs Ashwagandha: The NGF-Cortisol Effect Explained

← Back to Lion's Mane Research Hub